Research analysts at StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Rating) in a research note issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.
Aptevo Therapeutics Stock Up 1.7 %
NASDAQ APVO opened at $2.44 on Tuesday. The stock has a fifty day moving average of $2.62 and a 200-day moving average of $3.21. Aptevo Therapeutics has a 52 week low of $1.94 and a 52 week high of $7.55. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.16 and a quick ratio of 3.16.
Aptevo Therapeutics (NASDAQ:APVO – Get Rating) last released its earnings results on Thursday, November 10th. The biotechnology company reported ($1.53) EPS for the quarter, beating the consensus estimate of ($1.64) by $0.11. Analysts forecast that Aptevo Therapeutics will post -6.58 EPS for the current year.
Institutional Investors Weigh In On Aptevo Therapeutics
About Aptevo Therapeutics
Aptevo Therapeutics, Inc is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology.
- Get a free copy of the StockNews.com research report on Aptevo Therapeutics (APVO)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.